Pharmacy- Page 181

Roche ranked the most sustainable healthcare company in the DJSI

November 16, 2020

Pharmacy

The FINANCIAL — For the eleventh time, Roche has been recognised as the most sustainable company in the Pharmaceuticals index of the Dow Jones Sustainability Indices (DJSI). This is based on an in-depth analysis of economic, social and environmental performance. The DJSI family of indices serves as a benchmark for investors who integrate sustainability considerations into their portfolios. Roche has

Gilead and Novo Nordisk announced new data from proof-of-concept trial in NASH

The FINANCIAL — Gilead Sciences, Inc. and Novo Nordisk A/S announced results

by The FINANCIAL

November 16, 2020

2 mins read

Metagenomi closes USD 65 million Series A financing led by Leaps by Bayer and Humboldt Fund

The FINANCIAL — Metagenomi, a next generation gene editing company launched by

by The FINANCIAL

November 12, 2020

1 min read

Pharmaceutical industries join to promise fair access to COVID-19 medicines and vaccines

The FINANCIAL — On the occasion of the World Health Assembly, the world’s

by The FINANCIAL

November 12, 2020

1 min read

Pharmacy

Shire Saw Positive Results From Gaucher Drug Trial

The FINANCIAL -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, on August 3 reported positive results from the first of three Phase III studies of velaglucerase alfa, its enzyme replacement therapy in development for the treatment of Type 1 Gaucher

by The FINANCIAL

August 3, 2009

3 mins read

Pharmacy

Takeda Submits a New Drug Application for a Fixed-Dose Combination Tablet of Actos with sulfonylurea

The FINANCIAL -- Takeda Pharmaceutical Company Limited ("Takeda") announced on July 27 that it filed a New Drug Application to the Ministry of Health, Labour and Welfare for a fixed-dose combination tablet of Actos (generic name: pioglitazone HCI) with sulfonylurea for the treatment of

by The FINANCIAL

July 27, 2009

1 min read

Pharmacy

Agreements Concluded for “SELTOUCH Pap 70, 140”

The FINANCIAL — Wyeth K.K. (Headquarters: Shinagawa-ku, Tokyo, President & Representative Director Michael Goettler, “WKK”), ASKA Pharmaceutical Co., Ltd (Headquarters: Minato-ku, Tokyo, President, Representative Director Takashi Yamaguchi, “ASKA”) and Takeda Pharmaceutical Company Limited (Headquarters: Chuo-ku, Osaka, President & CEO Yasuchika Hasegawa, “Takeda”)

by The FINANCIAL

July 27, 2009

1 min read

Pharmacy

Nycomed announces FDA filing for Daxas in COPD

The FINANCIAL -- Nycomed on July 20 announced the submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for Daxas as a once-daily oral treatment for patients with symptomatic COPD. The NDA submission is based on encouraging results

by The FINANCIAL

July 20, 2009

1 min read

Pharmacy

Bristol-Myers Squibb’s SECURE THE FUTURE Announces $1.3 Million in New Grants

The FINANCIAL -- Bristol-Myers Squibb Company (NYSE: BMY) and the Bristol-Myers Squibb Foundation on July 20 announced new grants providing technical assistance and $1.3 million in funding to community-based organizations in Africa to enhance the care and support for people affected by HIV/AIDS.

by The FINANCIAL

July 20, 2009

1 min read

Pharmacy

ImClone Systems and Bristol-Myers Squibb Announce Revisions to ERBITUX

The FINANCIAL -- ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company (NYSE: LLY), and Bristol-Myers Squibb Company (NYSE: BMY) on July 20 announced that the U.S. Food and Drug Administration (FDA) has approved revisions to the U.S. prescribing information for ERBITUX (cetuximab)

by The FINANCIAL

July 20, 2009

2 mins read

Pharmacy

Xeloda in combination with oxaliplatin shown to be effective in early colon cancer

The FINANCIAL -- Roche announced on July 20 results from the international phase III study NO16968 (XELOXA), investigating oral Xeloda in combination with intravenous oxaliplatin (XELOX) immediately after surgery, which show that patients with colon cancer taking XELOX live disease free for longer compared

by The FINANCIAL

July 20, 2009

1 min read

Pharmacy

Human Genome Sciences and GlaxoSmithKline announce positive Phase 3 study results for Benlysta

The FINANCIAL -- Human Genome Sciences, Inc. (Nasdaq: HGSI) and GlaxoSmithKline PLC (GSK) on July 20 announced that Benlysta (belimumab, formerly LymphoStat-B) met the primary endpoint in BLISS-52, the first of two pivotal Phase 3 trials in patients with serologically active systemic lupus

by The FINANCIAL

July 20, 2009

3 mins read

Pharmacy

FDA Approves Plan B One-Step, a New One-Pill Emergency Contraceptive

The FINANCIAL -- Teva Pharmaceutical Industries, Ltd. (NASDAQ: TEVA) announced on July 13 that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Plan B One-Step emergency contraception (levonorgestrel tablet, 1.5 mg).

by The FINANCIAL

July 13, 2009

1 min read

Pharmacy

Bayer presents positive Phase II data with florbetaben

The FINANCIAL -- Bayer Schering Pharma AG, Germany, has presented positive data on a global Phase II study with the novel positron emission tomography (PET) tracer florbetaben (BAY 94-9172) at the International Conference on Alzheimer's Disease (ICAD) in Vienna, Austria.

by The FINANCIAL

July 13, 2009

1 min read